192 related articles for article (PubMed ID: 21284052)
1. Novel neoadjuvant immunotherapy regimen safety and survival in head and neck squamous cell cancer.
Wolf GT; Fee WE; Dolan RW; Moyer JS; Kaplan MJ; Spring PM; Suen J; Kenady DE; Newman JG; Carroll WR; Gillespie MB; Freeman SM; Baltzer L; Kirkley TD; Brandwein HJ; Hadden JW
Head Neck; 2011 Dec; 33(12):1666-74. PubMed ID: 21284052
[TBL] [Abstract][Full Text] [Related]
2. A phase 1 safety study of an IRX-2 regimen in patients with squamous cell carcinoma of the head and neck.
Freeman SM; Franco JL; Kenady DE; Baltzer L; Roth Z; Brandwein HJ; Hadden JW
Am J Clin Oncol; 2011 Apr; 34(2):173-8. PubMed ID: 20539208
[TBL] [Abstract][Full Text] [Related]
3. Combination immunotherapy of squamous cell carcinoma of the head and neck: a phase 2 trial.
Barrera JL; Verastegui E; Meneses A; Zinser J; de la Garza J; Hadden JW
Arch Otolaryngol Head Neck Surg; 2000 Mar; 126(3):345-51. PubMed ID: 10722007
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant immunotherapy of oral squamous cell carcinoma modulates intratumoral CD4/CD8 ratio and tumor microenvironment: a multicenter phase II clinical trial.
Tímár J; Ladányi A; Forster-Horváth C; Lukits J; Döme B; Remenár E; Godény M; Kásler M; Bencsik B; Répássy G; Szabó G; Velich N; Suba Z; Elo J; Balatoni Z; Pócza K; Zemplén B; Chretien P; Talor E
J Clin Oncol; 2005 May; 23(15):3421-32. PubMed ID: 15908653
[TBL] [Abstract][Full Text] [Related]
5. Covalent linking of proteins and cytokines to suture: enhancing the immune response of head and neck cancer patients.
Shibuya TY; Kim S; Nguyen K; Parikh P; Wadhwa A; Brockardt C; Do J
Laryngoscope; 2003 Nov; 113(11):1870-84. PubMed ID: 14603040
[TBL] [Abstract][Full Text] [Related]
6. Maintenance immunotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck.
Recchia F; Candeloro G; Di Staso M; Necozione S; Bisegna R; Bratta M; Tombolini V; Rea S
J Immunother; 2008 May; 31(4):413-9. PubMed ID: 18391754
[TBL] [Abstract][Full Text] [Related]
7. Immune changes in peripheral blood resulting from locally directed interleukin-2 therapy in squamous cell carcinoma of the head and neck.
Dadian G; Riches PG; Henderson DC; MacLennan K; Lorentzos A; Moore J; Hobbs JR; Gore ME
Eur J Cancer B Oral Oncol; 1993 Jan; 29B(1):29-34. PubMed ID: 8180573
[TBL] [Abstract][Full Text] [Related]
8. Interleukins and contrasuppression induce immune regression of head and neck cancer.
Hadden JW; Endicott J; Baekey P; Skipper P; Hadden EM
Arch Otolaryngol Head Neck Surg; 1994 Apr; 120(4):395-403. PubMed ID: 8166968
[TBL] [Abstract][Full Text] [Related]
9. A natural cytokine mixture (IRX-2) and interference with immune suppression induce immune mobilization and regression of head and neck cancer.
Verastegui E; Barrera JL; Zinser J; Del Rio R; Meneses A; De La Garza J; Hadden JW
Int J Immunopharmacol; 1997; 19(11-12):619-27. PubMed ID: 9669202
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the immune response in patients with cancer of the oral cavity after neoadjuvant immunotherapy with the IRX-2 regimen.
Liu S; Bellile E; Nguyen A; Zarins K; D'Silva N; Rozek L; Wolf GT; Sartor MA;
Oral Oncol; 2021 Dec; 123():105587. PubMed ID: 34717154
[TBL] [Abstract][Full Text] [Related]
11. Histologic findings in patients with head and neck squamous cell carcinoma receiving perilymphatic natural cytokine mixture (IRX-2) prior to surgery.
Meneses A; Verastegui E; Barrera JL; Zinser J; de la Garza J; Hadden JW
Arch Pathol Lab Med; 1998 May; 122(5):447-54. PubMed ID: 9593347
[TBL] [Abstract][Full Text] [Related]
12. Rationale for neoadjuvant immunotherapy in head and neck squamous cell carcinoma.
Hanna GJ; Adkins DR; Zolkind P; Uppaluri R
Oral Oncol; 2017 Oct; 73():65-69. PubMed ID: 28939078
[TBL] [Abstract][Full Text] [Related]
13. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
O'Malley BW; Li D; McQuone SJ; Ralston R
Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
[TBL] [Abstract][Full Text] [Related]
14. TPF induction chemotherapy and concomitant irradiation with cisplatin and cetuximab in unresectable squamous cell carcinoma of the head and neck.
Strojan P; Grašič Kuhar C; Žumer B; Kadivec M; Karner K; Fajdiga I; Jančar B; Gale N; Poljak M; Kocjan BJ; Zakotnik B
Head Neck; 2014 Nov; 36(11):1555-61. PubMed ID: 24123552
[TBL] [Abstract][Full Text] [Related]
15. Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma.
Nguyen N; Bellile E; Thomas D; McHugh J; Rozek L; Virani S; Peterson L; Carey TE; Walline H; Moyer J; Spector M; Perim D; Prince M; McLean S; Bradford CR; Taylor JM; Wolf GT;
Head Neck; 2016 Jul; 38(7):1074-84. PubMed ID: 26879675
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant immunotherapy for head and neck squamous cell carcinoma.
Kürten CHL; Ferris RL
Laryngorhinootologie; 2024 May; 103(S 01):S167-S187. PubMed ID: 38697147
[TBL] [Abstract][Full Text] [Related]
17. Phase 2 study of docetaxel, cisplatin, and concurrent radiation for technically resectable stage III-IV squamous cell carcinoma of the head and neck.
Inohara H; Takenaka Y; Yoshii T; Nakahara S; Yamamoto Y; Tomiyama Y; Seo Y; Isohashi F; Suzuki O; Yoshioka Y; Sumida I; Ogawa K
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):934-41. PubMed ID: 25832686
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy for Head and Neck Squamous Cell Carcinoma: A Review of Current and Emerging Therapeutic Options.
Moskovitz JM; Moy J; Seiwert TY; Ferris RL
Oncologist; 2017 Jun; 22(6):680-693. PubMed ID: 28507203
[TBL] [Abstract][Full Text] [Related]
19. A pilot study of perilymphatic leukocyte cytokine mixture (IRX-2) as neoadjuvant treatment for early stage cervical carcinoma.
Dueñas-Gonzalez A; Verastegui E; Lopez-Graniel C; Gonzalez A; Mota A; Barrera-Franco JL; Meneses A; Chanona J; de la Garza J; Chavez-Blanco A; Hadden JW
Int Immunopharmacol; 2002 Jun; 2(7):1007-16. PubMed ID: 12188025
[TBL] [Abstract][Full Text] [Related]
20. Expression and clinical significance of connective tissue growth factor in advanced head and neck squamous cell cancer.
Kikuchi R; Kikuchi Y; Tsuda H; Maekawa H; Kozaki K; Imoto I; Tamai S; Shiotani A; Iwaya K; Sakamoto M; Sekiya T; Matsubara O
Hum Cell; 2014 Jul; 27(3):121-8. PubMed ID: 24700237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
